重新审视散发性帕金森病与阿尔茨海默病中蛋白聚集的致病性
该文基于临床病理诊断金标准,指出散发性帕金森病(PD)和阿尔茨海默病(AD)中蛋白聚集在尸检中近乎普遍,但未必反映疾病起始的致病机制。作者提出三种概念框架(致病性、伴随现象、保护性),认为动物模型支持致病性而人类间接证据不支持,并假设当前生物标志物可能仅反映共同病理而非亚组致病机制。
要点
- PD和AD的尸检蛋白聚集是诊断金标准,但不一定代表发病起始的致病机制。
- 人类研究间接证据不支持蛋白聚集的致病性,而动物模型一致支持但自然状态不发病。
- 靶向寡聚体或纤维的疾病修饰治疗可能无效或有害,因蛋白聚集可能是伴随现象或保护性反应。
核心结论
- 散发性PD和AD中蛋白聚集在尸检中近乎普遍,但可能代表上游机制的共同结局或细胞应激的保护性反应,而非致病因素。
研究设计与样本
- 本文为基于文献综述的假说性文章,未报告系统检索范围或样本量。
主要发现
- 动物模型一致支持蛋白聚集的致病作用,但人类研究间接证据不支持。
- 当前蛋白聚集生物标志物可能与共同病理相关,但与亚组致病机制无关。
关键数值与推荐
- PD确诊金标准为α-突触核蛋白聚集形成路易小体,AD为淀粉样蛋白斑块和过度磷酸化tau缠结。
临床怎么用
- 未来精准医学的分子靶向治疗可能不应锚定于当前临床病理标准,而应基于大型深度表型衰老人群或遗传-分子队列的生物学信号。
局限性
- 无法实时探测脑组织,难以区分蛋白聚集的三种概念框架(致病性、伴随现象、保护性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles. Implicit in this clinicopathologic-based nosology is the assumption that pathologic protein aggregation at autopsy reflects pathogenesis at disease onset. While these aggregates may in exceptional cases be on a causal pathway in humans (e.g., aggregated α-synuclein in SNCA gene multiplication or aggregated β-amyloid in APP mutations), their near universality at postmortem in sporadic PD and AD suggests they may alternatively represent common outcomes from upstream mechanisms or compensatory responses to cellular stress in order to delay cell death. These 3 conceptual frameworks of protein aggregation (pathogenic, epiphenomenon, protective) are difficult to resolve because of the inability to probe brain tissue in real time. Whereas animal models, in which neither PD nor AD occur in natural states, consistently support a pathogenic role of protein aggregation, indirect evidence from human studies does not. We hypothesize that (1) current biomarkers of protein aggregates may be relevant to common pathology but not to subgroup pathogenesis and (2) disease-modifying treatments targeting oligomers or fibrils might be futile or deleterious because these proteins are epiphenomena or protective in the human brain under molecular stress. Future precision medicine efforts for molecular targeting of neurodegenerative diseases may require analyses not anchored on current clinicopathologic criteria but instead on biological signals generated from large deeply phenotyped aging populations or from smaller but well-defined genetic-molecular cohorts.
引用
- Espay AJ, Vizcarra JA, Marsili L, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019. PMID: 30745444. doi:10.1212/WNL.0000000000006926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。